
## Daniele De Martini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5715892/publications.pdf Version: 2024-02-01



DANIELE DE MADTINI

#	Article	IF	CITATIONS
1	Reproducibility probability estimation for testing statistical hypotheses. Statistics and Probability Letters, 2008, 78, 1056-1061.	0.4	21
2	Empowering phase II clinical trials to reduce phase III failures. Pharmaceutical Statistics, 2020, 19, 178-186.	0.7	21
3	Adapting by calibration the sample size of a phase III trial on the basis of phase II data. Pharmaceutical Statistics, 2011, 10, 89-95.	0.7	15
4	Stability criteria for the outcomes of statistical tests to assess drug effectiveness with a single study. Pharmaceutical Statistics, 2012, 11, 273-279.	0.7	7
5	Reproducibility Probability Estimation and RP-Testing for Some Nonparametric Tests. Entropy, 2016, 18, 142.	1.1	7
6	Conservative Sample Size Estimation in Nonparametrics. Journal of Biopharmaceutical Statistics, 2010, 21, 24-41.	0.4	6
7	Robustness and Corrections for Sample Size Adaptation Strategies Based on Effect Size Estimation. Communications in Statistics Part B: Simulation and Computation, 2011, 40, 1263-1277.	0.6	6
8	Profit Evaluations When Adaptation by Design Is Applied. Therapeutic Innovation and Regulatory Science, 2016, 50, 213-220.	0.8	2
9	Computing individual and collective ethical utility for optimally planning phase III trials. Biometrical Journal, 2018, 60, 1121-1134.	0.6	1
10	Improving reproducibility probability estimation and preserving RP-testing. Statistical Methods and Applications, 2021, 30, 49-77.	0.7	0
11	Reproducibility Probability Testing Kills P-value. SSRN Electronic Journal, 0, , .	0.4	0
12	Phase III Sample Size Based on the 'Power to Detect' Is Logically Wrong and Usually Unethical. SSRN Electronic Journal, 0, , .	0.4	0